Published in Blood on December 15, 2008
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Clonal evolution in cancer. Nature (2012) 11.07
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
The increasing complexity of the cancer stem cell paradigm. Science (2009) 5.45
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
Self-renewal as a therapeutic target in human colorectal cancer. Nat Med (2013) 4.20
Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat Biotechnol (2011) 3.81
Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol (2010) 3.27
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther (2009) 3.20
Dendritic cell homeostasis. Blood (2009) 3.18
Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol (2010) 3.13
Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet (2009) 2.69
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med (2015) 2.53
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer (2010) 2.20
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
Looking ahead in cancer stem cell research. Nat Biotechnol (2009) 1.89
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun (2011) 1.84
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood (2010) 1.79
Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol (2009) 1.78
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) (2014) 1.74
Targeting breast cancer stem cells. Mol Oncol (2010) 1.72
Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell (2012) 1.71
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A (2011) 1.71
Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol (2013) 1.70
Stem cell quiescence. Clin Cancer Res (2011) 1.69
Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol (2009) 1.68
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics (2015) 1.62
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50
Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer (2010) 1.50
Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res (2009) 1.46
Understanding the cancer stem cell. Br J Cancer (2010) 1.42
Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One (2013) 1.41
Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol (2012) 1.40
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Intratumor heterogeneity in evolutionary models of tumor progression. Genetics (2011) 1.31
Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med (2011) 1.29
Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res (2011) 1.26
Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene (2010) 1.26
TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep (2013) 1.24
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A (2010) 1.24
Colon cancer stem cells: implications in carcinogenesis. Front Biosci (Landmark Ed) (2011) 1.23
Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med (2012) 1.22
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res (2011) 1.18
Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors. PLoS One (2010) 1.17
The therapeutic potential of stem cells. Philos Trans R Soc Lond B Biol Sci (2010) 1.15
TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest (2011) 1.13
Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc (2014) 1.12
A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol (2010) 1.12
Cancer heterogeneity--a multifaceted view. EMBO Rep (2013) 1.11
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia (2011) 1.09
Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol (2013) 1.09
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res (2014) 1.09
Pig-a mutation: kinetics in rat erythrocytes following exposure to five prototypical mutagens. Toxicol Sci (2009) 1.06
Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal (2011) 1.05
Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood (2014) 1.04
A simple mathematical model based on the cancer stem cell hypothesis suggests kinetic commonalities in solid tumor growth. PLoS One (2012) 1.04
Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer (2014) 1.02
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) (2013) 1.01
Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling. Neoplasia (2011) 1.01
CD271 defines a stem cell-like population in hypopharyngeal cancer. PLoS One (2013) 1.00
Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget (2015) 0.99
Tumor heterogeneity and its implication for drug delivery. J Control Release (2012) 0.99
Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med (2010) 0.98
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer (2014) 0.97
Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell (2012) 0.97
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Pluripotent transcription factors possess distinct roles in normal versus transformed human stem cells. PLoS One (2009) 0.96
Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci Rep (2012) 0.96
EGFR controls IQGAP basolateral membrane localization and mitotic spindle orientation during epithelial morphogenesis. EMBO J (2014) 0.96
Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.95
Marker-independent method for isolating slow-dividing cancer stem cells in human glioblastoma. Neoplasia (2013) 0.95
Cancer stem cells as 'units of selection'. Evol Appl (2012) 0.94
Evidence that growth factor independence 1b regulates dormancy and peripheral blood mobilization of hematopoietic stem cells. Blood (2010) 0.94
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One (2014) 0.94
CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells. Leukemia (2013) 0.94
Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning (2015) 0.93
Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol (2011) 0.93
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. Blood (2012) 0.93
Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells (2010) 0.93